drugset / Trial / NCT01060475

Safety and Tolerability of LIM-0705 in Healthy Male Subjects

NCT01060475

Phase 1 Completed 44 enrolled Limerick BioPharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

LIM-0705 dosed separately and in combination with tacrolimus will be safe and well tolerated.

Timeline

Start
2010-02
Primary completion
2010-05
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject QUERCETIN-3'-O-PHOSPHATE Small molecule 500 mg Oral
Subject QUERCETIN-3'-O-PHOSPHATE Small molecule 750 mg Oral
Subject Tacrolimus Small molecule

Indications

No indication recorded.